Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | CLPP | Q16740 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2352442 | 0.84 | ALOX5 (0.51) | COMTCLPPCHRNB2CHRNA4CYP17A1 | |
| SCHEMBL2349760 | 0.82 | DRD4 (0.44) | CLPP | |
| SCHEMBL6910475 | 0.82 | KMT2A (0.41) | — | |
| SCHEMBL2347548 | 0.82 | KMT2A (0.51) | CLPP | |
| SCHEMBL2344993 | 0.80 | CLPP (0.49) | CLPP | |
| SCHEMBL2347296 | 0.79 | MEN1 (0.50) | COMTCLPPCYP17A1CYP3A4ALOX5 | |
| SCHEMBL2354947 | 0.78 | KDM4E (0.46) | CLPPGABRA1GABRA3GABRA2 | |
| SCHEMBL2345757 | 0.77 | KMT2A (0.40) | CLPP | |
| SCHEMBL2344024 | 0.76 | CYP17A1 (0.50) | COMTCLPPCYP17A1CYP3A4GABRA1 | |
| SCHEMBL2303175 | 0.76 | CLPP (0.53) | CLPPCHRNB2CHRNA4GABRA1GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | claimed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | claimed |
| EP-2361912-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | claimed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| US-8748456-B2 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2014-06-10 | — | — | US | disclosed |
| EP-2536721-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2012-12-26 | — | — | EP | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | GENKYOTEX SA (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2361912-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | disclosed |
| EP-2361912-A1 | Pyrazolo piperidine derivatives as NADPH oxidase inhibitors | GenKyoTex SA (CH) | 2011-08-31 | — | — | EP | disclosed |
| WO-2011101805-A1 | PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316380-A1 | Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors | NOX1, NOX4, NOX5 | COMT 1128/4885CLPP 2482/4885CHRNB2 1351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.